- Gold bounces alongside improvement in US President Trump’s health.
- Developments around Trump’s health to be the key decider.
- Gold stays below 21-DMA ahead of the US Markit, ISM Services PMIs.
Heading into a new week, the risk sentiment witnessed a major turnaround alongside the apparent improvement in US President Donald Trump’s health condition. The US dollar gave back a minor part of its last Friday’s surge amid the upbeat market mood, as Gold (XAU/USD) showed some signs of life around the $1900 mark. The ongoing optimism over the additional US fiscal stimulus also offered some support to the yieldless gold. The yellow metal gained over 2% last week, settling Friday below the $1900 level. Friday’s slide was courtesy of the resurgent haven demand for the greenback after Trump and his wife were diagnosed with COVID-19.
Looking ahead, the price action in gold will likely depend on the fresh updates concerning Trump’s health, especially after some of the medical experts noted that the president’s condition may be more severe, given fluctuating oxygen levels and a steroid drug treatment. The safe-haven dollar could regain poise and knockdown gold should Trump’s condition deteriorate. In contrast, gold could extend the bounce in case of early discharge from the hospital. Also, of note remains the US Services PMI reports from both Markit and ISM for fresh trading impetus ahead of Wednesday’s FOMC September meeting minutes.
Gold: Short-tern technical outlook
As observed in the daily chart, gold’s upside attempts likely to remain capped while it trades below the 21-day Simple Moving Average (DMA) at $1915.
Meanwhile, to the downside, the upward-sloping 100-DMA at $1856 could continue to offer support, leaving the prices in a narrow range.
A breakout on either side could trigger a substantial move, although the path of least resistance appears to the downside amid a bearish 14-day Relative Strength Index (RSI), currently at 44.86.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.